Selected publication milestones, not an exhaustive history or discovery priority claim.
2010 — Randomized assigned lifestyle improves NAS and steatosis; current component definitions and achieved-loss strata remain distinct. Original PMID19827166.
2011 — A shared lifestyle-trial molecular follow-up adds ceramide leads rather than an independent clinical outcome unit. Original PMID21794038.
2013 — Mediterranean-diet fat improvement without different loss separates diet composition from weight mediation. Original PMID23485520.
2015 — Large paired-biopsy lifestyle cohort makes achieved-loss resolution and regression associations visible. Original PMID25865049.
2016 — LEAN supplies a distinct randomized drug histology positive with incomplete endpoint biopsies. Original PMID26608256.
2016 — Pioglitazone improves pathology despite weight gain, challenging universal weight-loss necessity. Original PMID27322798.
2017 — Weight-maintained exercise reduces hepatic fat without proving inflammation or fibrosis reversal. Original PMID27521509.
2018 — FLINT achieved-weight posthoc analysis illustrates additive response and nonrandom mediation limits. Original PMID29333665.
2019 — Obeticholic acid separates a fibrosis positive from a nonsignificant steatohepatitis-resolution outcome. Original PMID31813633.
2020 — Five-year bariatric biopsies reveal durable observed resolution/regression with selective follow-up. Original PMID32553765.
2021 — Daily semaglutide shows resolution efficacy while categorical fibrosis is nonsignificant. Original PMID33185364.
2021 — Lanifibranor demonstrates clinical-pathology efficacy despite weight gain and dose-specific significance. Original PMID34670042.
2021 — SPLENDOR contributes observational long-term surgery-event evidence rather than a surrogate-based lifestyle proof. Original PMID34762106.
2023 — Randomized diet metabolic/weight improvements do not guarantee a biopsy difference. Original PMID36508737.
2023 — Compensated cirrhosis semaglutide has weight/MRI-fat benefit without a positive histologic endpoint. Original PMID36934740.
2023 — BRAVES provides an actual surgery-versus-lifestyle/best-care randomized biopsy comparison. Original PMID37088093.
2024 — MAESTRO-NASH establishes resmetirom histology efficacy for a separate liver-directed exposure. Original PMID38324483.
2024 — SYNERGY-NASH adds tirzepatide pathology positives, with missing biopsies and an attached erratum. Original PMID38856224.
2024 — A newer small lifestyle RCT reports explicit component/resolution benefits with average fibrosis unchanged and an unresolved count discrepancy. Original PMID38914313.
2025 — ESSENCE interim 72-week semaglutide pathology positives precede its ongoing longer clinical phase. Original PMID40305708.
2025 — SYNERGY responder/mediation analysis generates weight-related leads without randomized mediator identity. Original PMID41066427.
2026 — Older-adult GLP1 cohort associates exposure with hepatic outcomes while MACE is null; observational event evidence remains separate. Original PMID42765724.
Independent adequately powered current-resolution replication of assigned lifestyle in baseline MASH.
Source clarification of the nine-resolution/eight-ballooning-zero inconsistency in PMID38914313.
Isolated weight versus activity, diet composition and peripheral metabolic mediation.
Prospective stage/diabetes interaction mapping and paired-biopsy missingness sensitivity.
Controlled lifestyle fibrosis improvement and durability beyond active histology response.
Hard hepatic events and harms beyond short selected cohorts; full supplements and all complete papers remain unaudited.
A multicentre lifestyle-versus-matched-support randomized trial enrolls baseline-biopsy MASH adults, stratifies fibrosis stage and diabetes before outcomes, and measures independently read paired inflammation/ballooning resolution at 52–104 weeks. Factorial diet/exercise and prospectively controlled energy/weight trajectories distinguish package efficacy from isolated mediator claims; retain all assigned participants and specify missing-biopsy sensitivity analyses. Extend blinded hepatic event follow-up.